OA12494A - Inhibitor of monoamine uptake. - Google Patents

Inhibitor of monoamine uptake. Download PDF

Info

Publication number: OA12494A
Authority: OA; OAPI
Prior art keywords: methyl; phenyl; oxy; compound; aminopropane
Prior art date: 2001-03-06

Application number

OA1200300215A

Other languages

English (en)

Inventor

Edward Louis Mattiuz

John Michael Sauer

William Joe Wheeler

David Taiwai Wong

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-03-06

Filing date

2002-02-20

Publication date

2006-05-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23045157&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=OA12494(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-02-20 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2006-05-24 Publication of OA12494A publication Critical patent/OA12494A/en

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/48—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Addiction (AREA)
Psychiatry (AREA)
Endocrinology (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Reproductive Health (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Immunology (AREA)
Gynecology & Obstetrics (AREA)
Child & Adolescent Psychology (AREA)
Hospice & Palliative Care (AREA)
Anesthesiology (AREA)
Otolaryngology (AREA)
Diabetes (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

OA1200300215A 2001-03-06 2002-02-20 Inhibitor of monoamine uptake. OA12494A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US27373001P	2001-03-06	2001-03-06

Publications (1)

Publication Number	Publication Date
OA12494A true OA12494A (en)	2006-05-24

Family

ID=23045157

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200300215A OA12494A (en)	2001-03-06	2002-02-20	Inhibitor of monoamine uptake.

Country Status (35)

Country	Link
US (2)	US20040082666A1 (lt)
EP (1)	EP1379492B1 (lt)
JP (1)	JP2004525912A (lt)
KR (1)	KR20030092012A (lt)
CN (1)	CN1229331C (lt)
AP (1)	AP2003002855A0 (lt)
AT (2)	ATE396170T1 (lt)
AU (1)	AU2002245385B2 (lt)
BR (1)	BR0207716A (lt)
CA (1)	CA2440161A1 (lt)
CH (1)	CH695982A5 (lt)
CZ (1)	CZ20032380A3 (lt)
DE (1)	DE60226715D1 (lt)
DK (1)	DK200301267A (lt)
EA (1)	EA005768B1 (lt)
EC (1)	ECSP034760A (lt)
EE (1)	EE200300419A (lt)
ES (2)	ES2201942B2 (lt)
FI (1)	FI20031191A7 (lt)
GB (1)	GB2389851B (lt)
HR (1)	HRP20030710A2 (lt)
HU (1)	HUP0303341A3 (lt)
IL (1)	IL157779A0 (lt)
LT (1)	LT5143B (lt)
LU (1)	LU91038B1 (lt)
LV (1)	LV13119B (lt)
NO (1)	NO20033921L (lt)
NZ (1)	NZ527431A (lt)
OA (1)	OA12494A (lt)
PL (1)	PL363840A1 (lt)
SE (1)	SE526598C2 (lt)
SK (1)	SK10632003A3 (lt)
TR (1)	TR200705146T1 (lt)
WO (1)	WO2002070457A1 (lt)
ZA (1)	ZA200306882B (lt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EA005768B1 (ru) *	2001-03-06	2005-06-30	Эли Лилли Энд Компани	Ингибирование поглощения моноамина
EP1660065A2 (en) *	2003-08-27	2006-05-31	Eli Lilly And Company	Treatment of pervasive developmental disorders with norepinephrine reuptake inhibitors
DE602004014823D1 (de) *	2003-12-12	2008-08-14	Lilly Co Eli	Selektive norepinephrin-wiederaufnahmehemmer zur behandlung von hitzewallungen
WO2011027359A2 (en) *	2009-07-30	2011-03-10	Matrix Laboratories Ltd	Novel process for the preparation of 4-hydroxy atomoxetine
WO2012020418A1 (en)	2010-08-12	2012-02-16	Matrix Laboratories Ltd	Novel polymorphs of 4-hydroxy atomoxetine hydrochloride
DE102013022397A1 (de)	2013-12-19	2016-07-07	Metrax Gmbh	Vorrichtung zur Unterstützung eines Ersthelfers bei der Herzdruckmassage
GR1008819B (el)	2015-05-22	2016-08-01	Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων	Φαρμακευτικο σκευασμα που περιλαμβανει ατομοξετινη και μεθοδος παρασκευης αυτου
CN107935848B (zh) *	2017-11-21	2020-12-22	中国农业科学院兰州畜牧与兽药研究所	一种六茜素衍生物及其制备方法和应用
MX2021004883A (es) *	2018-10-31	2021-08-05	Apnimed Inc Delaware	Metodos y composiciones para tratar apnea del sue?o.

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4314081A (en) *	1974-01-10	1982-02-02	Eli Lilly And Company	Arloxyphenylpropylamines
US4194009A (en)	1974-01-10	1980-03-18	Eli Lilly And Company	Aryloxyphenylpropylamines for obtaining a psychotropic effect
US4018895A (en)	1974-01-10	1977-04-19	Eli Lilly And Company	Aryloxyphenylpropylamines in treating depression
FR2432500A1 (fr) *	1978-02-24	1980-02-29	Roussel Uclaf	Nouveaux derives de la benzene propanamine et leurs sels, procede de preparation et application a titre de medicaments
US5112619A (en) *	1985-11-12	1992-05-12	Eli Lilly And Company	Orally administerable sustained release pharmaceutical formulation
US4956388A (en)	1986-12-22	1990-09-11	Eli Lilly And Company	3-aryloxy-3-substituted propanamines
CA1327795C (en) *	1987-08-14	1994-03-15	Jules Freedman	Antidepressants which are aryloxy inadanamines
AU642582B2 (en) *	1991-02-25	1993-10-21	Eli Lilly And Company	Treatment of lower urinary tract disorders
TW514634B (en)	1997-10-14	2002-12-21	Lilly Co Eli	Process to make chiral compounds
WO2000058262A1 (en)	1999-03-29	2000-10-05	Eli Lilly And Company	Stereospecific method for preparing tomoxetine and intermediates thereof
JP2002541235A (ja)	1999-04-09	2002-12-03	イーライ・リリー・アンド・カンパニー	３−アリールオキシ−３−アリールプロピルアミン及びその中間体の製造方法
HRP20030384A2 (en) *	2000-11-15	2003-08-31	Lilly Co Eli	Treatment of anxiety disorders
EA005768B1 (ru) *	2001-03-06	2005-06-30	Эли Лилли Энд Компани	Ингибирование поглощения моноамина

2002
- 2002-02-20 EA EA200300978A patent/EA005768B1/ru not_active IP Right Cessation
- 2002-02-20 AT AT02713538T patent/ATE396170T1/de not_active IP Right Cessation
- 2002-02-20 AP APAP/P/2003/002855A patent/AP2003002855A0/en unknown
- 2002-02-20 OA OA1200300215A patent/OA12494A/en unknown
- 2002-02-20 IL IL15777902A patent/IL157779A0/xx unknown
- 2002-02-20 JP JP2002569778A patent/JP2004525912A/ja not_active Ceased
- 2002-02-20 BR BR0207716-7A patent/BR0207716A/pt not_active IP Right Cessation
- 2002-02-20 EP EP02713538A patent/EP1379492B1/en not_active Revoked
- 2002-02-20 CA CA002440161A patent/CA2440161A1/en not_active Abandoned
- 2002-02-20 TR TR2007/05146T patent/TR200705146T1/xx unknown
- 2002-02-20 ES ES200350052A patent/ES2201942B2/es not_active Expired - Fee Related
- 2002-02-20 FI FI20031191A patent/FI20031191A7/fi not_active IP Right Cessation
- 2002-02-20 LU LU91038A patent/LU91038B1/fr active
- 2002-02-20 DE DE60226715T patent/DE60226715D1/de not_active Revoked
- 2002-02-20 AT AT0904202A patent/AT414238B/de not_active IP Right Cessation
- 2002-02-20 HR HR20030710A patent/HRP20030710A2/hr not_active Application Discontinuation
- 2002-02-20 KR KR10-2003-7011635A patent/KR20030092012A/ko not_active Ceased
- 2002-02-20 AU AU2002245385A patent/AU2002245385B2/en not_active Ceased
- 2002-02-20 HU HU0303341A patent/HUP0303341A3/hu unknown
- 2002-02-20 US US10/468,553 patent/US20040082666A1/en not_active Abandoned
- 2002-02-20 WO PCT/US2002/003385 patent/WO2002070457A1/en not_active Ceased
- 2002-02-20 GB GB0323169A patent/GB2389851B/en not_active Expired - Fee Related
- 2002-02-20 ES ES02713538T patent/ES2305221T3/es not_active Expired - Lifetime
- 2002-02-20 SK SK1063-2003A patent/SK10632003A3/sk unknown
- 2002-02-20 EE EEP200300419A patent/EE200300419A/xx unknown
- 2002-02-20 CN CNB028060253A patent/CN1229331C/zh not_active Ceased
- 2002-02-20 CH CH01522/03A patent/CH695982A5/de not_active IP Right Cessation
- 2002-02-20 NZ NZ527431A patent/NZ527431A/en unknown
- 2002-02-20 PL PL02363840A patent/PL363840A1/xx not_active Application Discontinuation
- 2002-02-20 CZ CZ20032380A patent/CZ20032380A3/cs unknown
2003
- 2003-08-11 LT LT2003075A patent/LT5143B/lt unknown
- 2003-09-02 EC EC2003004760A patent/ECSP034760A/es unknown
- 2003-09-03 ZA ZA200306882A patent/ZA200306882B/en unknown
- 2003-09-03 SE SE0302361A patent/SE526598C2/sv not_active IP Right Cessation
- 2003-09-04 DK DK200301267A patent/DK200301267A/da not_active Application Discontinuation
- 2003-09-04 NO NO20033921A patent/NO20033921L/no not_active Application Discontinuation
- 2003-09-10 LV LVP-03-100A patent/LV13119B/en unknown
2005
- 2005-05-09 US US11/125,348 patent/US7384983B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US20050209341A1 (en)	2005-09-22
HUP0303341A3 (en)	2007-03-28
ZA200306882B (en)	2004-12-03
AT414238B (de)	2006-10-15
SE0302361D0 (sv)	2003-09-03
SK10632003A3 (sk)	2004-06-08
US20040082666A1 (en)	2004-04-29
ES2201942A1 (es)	2004-03-16
NZ527431A (en)	2005-05-27
CZ20032380A3 (en)	2004-03-17
LU91038B1 (fr)	2003-09-11
CA2440161A1 (en)	2002-09-12
WO2002070457A1 (en)	2002-09-12
EP1379492B1 (en)	2008-05-21
DE60226715D1 (de)	2008-07-03
EE200300419A (et)	2004-02-16
CH695982A5 (de)	2006-11-15
JP2004525912A (ja)	2004-08-26
HUP0303341A2 (hu)	2004-01-28
EA005768B1 (ru)	2005-06-30
WO2002070457A8 (en)	2004-06-03
CN1229331C (zh)	2005-11-30
IL157779A0 (en)	2004-03-28
GB0323169D0 (en)	2003-11-05
ECSP034760A (es)	2003-10-28
AP2003002855A0 (en)	2003-08-20
ATE396170T1 (de)	2008-06-15
GB2389851B (en)	2005-05-25
FI20031191L (fi)	2003-08-25
CN1494526A (zh)	2004-05-05
LT2003075A (lt)	2004-03-25
ATA90422002A (de)	2006-01-15
HRP20030710A2 (en)	2004-08-31
NO20033921D0 (no)	2003-09-04
SE526598C2 (sv)	2005-10-18
DK200301267A (da)	2003-11-06
LV13119B (en)	2004-06-20
NO20033921L (no)	2003-11-05
TR200705146T1 (tr)	2008-02-21
SE0302361L (sv)	2003-09-03
EP1379492A1 (en)	2004-01-14
GB2389851A (en)	2003-12-24
AU2002245385B2 (en)	2007-01-18
US7384983B2 (en)	2008-06-10
BR0207716A (pt)	2004-03-23
ES2305221T3 (es)	2008-11-01
KR20030092012A (ko)	2003-12-03
LT5143B (lt)	2004-06-25
PL363840A1 (pl)	2004-11-29
ES2201942B2 (es)	2004-12-16
EA200300978A1 (ru)	2004-02-26
FI20031191A7 (fi)	2003-08-25

Publication	Publication Date	Title
CA3160899C (en)	2024-04-16	Spiro compound serving as erk inhibitor, and application thereof
US7531685B2 (en)	2009-05-12	Deuterium-enriched oxybutynin
US11905276B2 (en)	2024-02-20	Bicyclic compound that acts as CRBN protein regulator
US9108902B2 (en)	2015-08-18	Deuterated 2-amino-3-hydroxypropanoic acid derivatives
US20110288179A1 (en)	2011-11-24	Bimatoprost crystalline form i
JP3708957B2 (ja)	2005-10-19	（−）−エゼロリン、（−）−ｎ１−ノルエゼロリンおよび（−）−ｎ１−ベンジルノルエゼロリンの置換フェンゼリンおよびフェニルカルバミン酸塩：特異的アセチルコリンエステラーゼ阻害薬としての使用
HK63992A (en)	1992-08-28	1-phenyl-3-naphthalenyloxy-propanamines
US20070032555A1 (en)	2007-02-08	Novel aryloxyphenyl-propanamines
OA12494A (en)	2006-05-24	Inhibitor of monoamine uptake.
AU2002245385A1 (en)	2003-03-13	Inhibitor of monoamine uptake
US20090149544A1 (en)	2009-06-11	Alpha-aminoamide derivatives
AU2007201684A1 (en)	2007-05-03	Inhibitor of monoamine uptake
US7183319B2 (en)	2007-02-27	Phenylethylamine derivatives and their use in the treatment of melanoma
US20110152227A1 (en)	2011-06-23	Deuterium labelled derivatives of 3-(2-hydroxy-5-methyphenyl)-n,n-diisopropyl-3-phenylpropylamine and methods of use thereof
US20220033376A1 (en)	2022-02-03	Estrogen receptor antagonist
US20080312318A1 (en)	2008-12-18	Deuterium-enriched escitalopram
CN119264131A (zh)	2025-01-07	Nmt抑制剂及其制备方法和用途
CN101336226A (zh)	2008-12-31	具有5-羟色胺能活性和/或去甲肾上腺素能活性的取代的苯乙胺
JPH0772168B2 (ja)	1995-08-02	グアニジノ安息香酸エステル誘導体